Meditip's Trodelbi (Sacituzumabgovitecan), an orphan drug triple-negative breast cancer treatment, has received domestic product approval. The Ministry of Food and Drug Safety (Minister Oh Yoo-kyung) announced on the 9th that it had approved the approval of Trodelbi to be used in breast cancer patients who lack estrogen receptor (ER), progesterone receptor (PR), and epidermal growth factor receptor 2 (HER2).

Trodelbi is an antibody-drug conjugate that targets Trop-2 protein, frequently found on the surface of breast cancer cells, and provides a new treatment opportunity for patients with advanced or metastatic triple-negative breast cancer. Trop-2 is overexpressed on the surface of various cancer cells, in